Methods of treating disease with nitric oxide (NO)-releasing...

Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S423000, C424S078370, C514S611000

Reexamination Certificate

active

08062656

ABSTRACT:
The invention provides NO-releasing polymers and low molecular weight NO-releasing compounds which may be used to for the treatment of medical conditions associated with NO-deficiency. The NO-releasing polymers or the low molecular weight NO-releasing compounds may also be incorporated into medical devices. The invention further provides methods of controlled release of NO for the treatment of diseases and disorders associated with NO-deficiency, wherein the treatment includes systemic or local administration of the NO-releasing polymers or the low molecular weight NO-releasing compounds.

REFERENCES:
patent: 6379660 (2002-04-01), Saavedra et al.
patent: 7776997 (2010-08-01), Mohanty et al.
patent: 7915377 (2011-03-01), Mohanty et al.
patent: 2005/0203272 (2005-09-01), Mohanty et al.
patent: 2006/0155103 (2006-07-01), Mohanty et al.
U.S. Appl. No. 12/105,869, filed Apr. 18, 2008, Mohanty.
Berger, K. et al., “Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rates,” Brain Research Bulletin (1991) 26:301-307.
Boje, K.M.K., “Nitric oxide neurotoxicity in neurodegenerative diseases,” Frontiers in Bioscience (2004) 9:763-776.
Columbia-Presbyterian Medical Center, “Nitric oxide in Parkinson's,” Biomedical Frontiers (1997) 4(2):1.
Fingl et al., “The Pharmacological Basis of Therapeutics,” Goodman & Gilman's, Chapter 1, p. 1-46 (1975).
Frost, M.C. et al., “Preparation and characterization of implantable sensors with nitric oxide release coatings,” Microchem. J. (2003) 74(3):277-288.
Frost, M.C. et al., “Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contacting medical devices,” Biomaterials (2005) 26(14):1685-1693.
Gonzalez-Zulueta, M. et al., “Requirement for nitric oxide activation of p2 lras/extracellular regulated kinase in neuronal ischemic preconditioning,” Proc. Natl. Acad. Sci. (2000) 97:436-441.
Guix, F. et al., “The physiology and pathophysiology of nitric oxide in the brain,” Progress in Neurobiology (2005) 76:126-152.
Heales, S.J.R. et al., “Neurodegeneration or neuroprotection: the pivotal role of astrocytes,” J. Neurochem. Res. (2004) 29(3):513-519.
Mohanakumar, K.P. et al., “Neuroprotection by nitric oxide against hydroxyl radical-induced nigral neurotoxicity,” J. Chem. Neuroanat. (1998) 14(3-4):195-205.
Mohanakumara, K.P. et al., “Nitric oxide: an antioxidant and neuroprotector,” Ann. N.Y. Acad. Sci. (2002) 962:389-401.
Oh, J.D. et al., “Protein kinase a inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat,” Neuroscience Letters (1997) 228(1):5-8.
Pan, Z-H, et al., “Nitric-oxide-related species inhibit evoked neurotransmission by enhance spontaneous miniature synaptic currents in central neuronal cultures,” Proc. Natl. Acad. Sci. USA (1996) 93(26):15423-15428.
Rauhala, P. et al., “Neuroprotection by S-nitrosoglutathione of brain dopamine neurons from oxidative stress,” FASEB J. (1998) 12:165-173.
Reynolds, M.M. et al., “Nitric oxide-releasing hydrophobic polymers: preparation, characterization, and potential biomedical applications,” Free Radical Biology & Medicine (2004) 37(7):926-936.
Thomas, T. et al., “L-deprenyl: nitric oxide production and dilation of cerebral blood vessels,” NeuroReport (1998) 9(1):2595-2600.
Tillerson, J.L et al., “Exercise induced behavioral recovery and attenuates neurochemical deficits in roden models of Parkinson's disease,” Neurosci. (2003) 119:899-911.
Vidwans, A.S. et al., “Analysis of the neuroprotective effects of various nitric oxide donor compounds in murine mixed cortical cell culture,” J. Neurochem. (1999) 72(5):1843-1852.
Wu, Y. et al., “Nitric oxide-releasing/generating polymers for the development of implantable chemical sensors with enhanced biocompatibility,” Talanta (2008) 75(3):642-650.
Zigmond, M.J. et al., “Pathophysiology of Parkinson's disease,” Neuropsychopharmacology: The Fifth Generation of Progress, eds. Davis, K.L. et al., American College of Neuropsychopharmacology (2002) 1781-1794.
United States Patent Office Action for U.S. Appl. No. 12/105,869 dated Apr. 26, 2011 (19 pages).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods of treating disease with nitric oxide (NO)-releasing... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating disease with nitric oxide (NO)-releasing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating disease with nitric oxide (NO)-releasing... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4279656

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.